Daflon. For Heavy, Painful legs and Varicose Veins

No. 1 Doctor recommended venoactive drug worldwide. 1

How does Daflon work?

wave icon

Venoactive treatments, like Daflon, are designed to help improve our leg vein health by strengthening our venous tone, which continue to weaken as chronic venous insufficiency progresses.

Daflon is acting at the core of chronic venous insufficiency, which inhibits venous inflammation, improves venous tone, anti-inflammation at the microvalve, improves lymphatic drainage and improves capillary hyperpermeability for improving and relieving signs and symptoms such as leg pain, heaviness, cramps and edema. 2,3,4,5

Tackle leg pain from the inside

wave icon

Daflon is a clinically proven, effective and convenient oral treatment derived from immature oranges and specially formulated for maximum absorption.

This improved absorption means Daflon can get to the root of the problem and effectively treat veins from the inside, improving the tone of veins, potentially protecting against disease progression and providing relief from heavy, painful leg symptoms. 2,3

Demonstrated effect of Daflon Over 8 weeks

4 weeks 4

8 weeks 4

Leg pain

50%

63%

Sensation of heaviness

50%

65%

Sensation of swelling

50%

72%

Relieves Symptoms

wave icon

Daflon is the No. 1 doctor recommended venoactive drug worldwide. 1

Clinical Studies have shown that Daflon can reduce leg pain and the sensations of heaviness and swelling by up to 50% after only one month of use. These figures were even higher after two months of treatment. 4

To benefit from your Daflon treatment, you should take your medication as recommended. Be sure to monitor your condition closely and speak with your family doctor if you have any concerns.

Daflon. Naturally sourced, scientifically prepared.

wave icon

The active ingredient in Daflon is a unique micronized purified flavonoid fraction (MPFF) containing 5 flavonoids, 90% micronized diosmin and 10% other active flavonoids (hesperidin, diosmetin, linarin and isorhoifolin). 9,10

Daflon's flavonoids are extracted from immature oranges that are rich in these naturally occurring plant chemicals. The compounds undergo a process of purification and refinement where the particles are made to collide with each other at high speeds (micronization), reducing them to tiny particles, less than 2 μm in size (micronized). These smaller particles are absorbed twice as easy by the body and a key ingredient of Daflon's success as a treatment for improving vein health and tone in Chronic Venous Insufficiency, anal tissues, and cushions. 6,9

Safety Information:

Daflon 500mg Safety Information

COMPOSITION*: Micronized, purified flavonoid fraction 500 mg: 450 mg diosmin; 50 mg flavonoids expressed as hesperidin.

INDICATIONS*: Treatment of organic and idiopathic chronic venous insufficiency of the lower limbs with the following symptoms: heavy legs; pain; nocturnal cramps. Treatment of acute hemorrhoidal attacks.

DOSAGE AND ADMINISTRATION*: In venous disease: 2 tablets daily. In acute hemorrhoidal attacks: the dosage can be increased to up to 6 tablets daily.

CONTRAINDICATIONS*: Hypersensitivity to the active substance or to any of the excipients.

WARNINGS*: The administration of this product for the symptomatic treatment of acute hemorrhoids does not preclude treatment for other anal conditions. If symptoms do not subside promptly, a proctological examination should be performed and the treatment should be reviewed.

INTERACTION(S)*: None.

FERTILITY*. PREGNANCY/LACTATION*: Treatment should be avoided.

DRIVE & USE MACHINES*. UNDESIRABLE EFFECTS*: Common: diarrhoea, dyspepsia, nausea, vomiting. Rare: dizziness, headache, malaise, rash, pruritus, urticaria. Uncommon: colitis. Frequency not known abdominal pain, isolated face, lip, eyelid oedema. Exceptionally Quincke’s oedema.

OVERDOSE*. PROPERTIES*: Vascular protector and venotonic. Daflon 500 mg acts on the return vascular system: it reduces venous distensibility and venous stasis; in the microcirculation, it normalizes capillary permeability and reinforces capillary resistance.

PRESENTATION*: Pack of 30 film-coated tablets of Daflon 500 mg.

Servier Hong Kong Limited Room103, 31/F, Tower 5, The Gateway, 15 Canton Road, Harbour City, Tsim Sha Tsui, Kowloon, Hong Kong. www.servier.hk

*For complete information, please refer to the Summary of Product Characteristics.

Daflon 1000mg Safety Information

COMPOSITION*: Micronized, purified flavonoid fraction 1000 mg: 900 mg diosmin; 100 mg flavonoids expressed as hesperidine.

INDICATIONS*: Treatment of the symptoms of chronic venous disease of the lower limbs, either organic or functional: feeling of heavy legs, pain, night cramps. Treatment of acute hemorrhoidal episodes.

DOSAGE AND ADMINISTRATION*: In venous disease: 1000mg daily. In acute hemorrhoidal attacks: the dosage can be increased up to 3000mg daily.

CONTRAINDICATIONS*: Hypersensitivity to the active substance or to any of the excipients.

WARNINGS*: The administration of this product for the symptomatic treatment of acute hemorrhoids does not preclude treatment for other anal conditions. If symptoms do not subside promptly, a proctological examination should be performed and the treatment should be reviewed.

INTERACTION(S)*: None.

FERTILITY/PREGNANCY/LACTATION*: Treatment should be avoided.

DRIVE & USE MACHINES/UNDESIRABLE EFFECTS*: Common: diarrhoea, dyspepsia, nausea, vomiting. Rare: dizziness, headache, malaise, rash, pruritus, urticaria. Uncommon: colitis. Frequency not known abdominal pain, isolated face, lip, eyelid oedema. Exceptionally Quincke’s oedema.

OVERDOSE/PROPERTIES*: Vascular protector and venotonic. Daflon 500 mg acts on the return vascular system: it reduces venous distensibility and venous stasis; in the microcirculation, it normalizes capillary permeability and reinforces capillary resistance.

PRESENTATION*: Pack of 30 film-coated tablets of Daflon 500 mg.

Servier Hong Kong Limited Room103, 31/F, Tower 5, The Gateway, 15 Canton Road, Harbour City, Tsim Sha Tsui, Kowloon, Hong Kong. www.servier.hk

*For complete information, please refer to the complete Summary of Product Characteristics for your country. 08/2021

References:

  1. IQVIA Daflon sales data MAT Q2 2021
  2. Nicolaides A, et al. Part I. Int Angiol. 2018;37(3):181-254.
  3. Maggioli A. Phlebolymphology. 2016;23(2):82-91
  4. Gilly R, et al. Phlebology. 1994;9:67-70.
  5. Cyrino FZ. et al. Int Angiol. 2021; 40(5):388-394 DOI: 10.23736/S0392-9590.21.04726-X
  6. Garner RC, et al. J Pharm Sci. 2002;91(1):32-40.
  7. Pascarella L, et al. Eur J Vasc Endovasc Surg. 2008;35(1):102-110. DOI:10.1016/j.ejvs.2007.08.011,
  8. Eberhardt RT, et al. Circulation 2014; 130(4): 333-346.
  9. Godeberge P, et al. J Comp Eff Res 2021;10(10):801-813.
  10. Daflon Summary of Product Characteristics

2024